A Preclinical and Clinical Overview of the Nucleotide-Based Antiviral Agent Cidofovir (HPMPC)
- 1 January 1996
- book chapter
- Published by Springer Nature
- Vol. 394, 105-115
- https://doi.org/10.1007/978-1-4757-9209-6_12
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- A Comparative Trial of Didanosine or Zalcitabine after Treatment with Zidovudine in Patients with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1994
- Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxy-propyl)cytosine (HPMPC) in vero cellsBiochemical Pharmacology, 1993
- Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigsAntiviral Research, 1990
- Synthesis and antiviral activity of the nucleotide analog (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cystosineJournal of Medicinal Chemistry, 1989
- (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replicationAntimicrobial Agents and Chemotherapy, 1988
- Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidinesAntiviral Research, 1987
- Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus.Proceedings of the National Academy of Sciences, 1985